New Microarray technology to check bird 'flu

USA - A new technology, named glycan microarray, can identify pathogens in a few hours and give advance warning of the ability of a virus to infect humans.

This could prove vital in efforts to control the spread of bird ‘flu, say its inventors, who work on the Consortium for Functional Glycomics (CFG), a project of the National Institute of Health’s National Institute of General Medical Sciences. CFG members work at the Scripps Research Institute, in cooperation with Mount Sinai School of Medicine and the Armed Forces Institute of Pathology, have now offered this new technology free to virus researchers.

Generally, thousands of DNA samples can be deposited in microarrays. However, for many pathogens it is the carbohydrates on the surface of most human or bird cells that provide a binding site, and once bound, a virus can then penetrate the host cell, which causes infections. The CFG was established to ascertain what carbohydrates coat which cells, and to catalogue their vulnerability to infections from various pathogens. Thus, in their new microarray, the researchers spread glycans (carbohydrate) molecules across the whole array. ‘Our technology allows hundreds of different varieties to be put on a single glycan array,’ explained Jeremy Berg, Director of the National Institute of General Medical Sciences. ‘There’s a universe of carbohydrates on the surface of cells. Our technology was not developed specifically for influenza. It is a very broad research tool.’
However, if an influenza virus, for example, is introduced, the hemagglutinin (HA) - glycoprotein on its surface - binds to the surface carbohydrates of a host cell and, using a tagged antibody, the technology could recognize the particular carbohydrate, from human or bird cell, to which the hemagglutinin has bound.

01.05.2006

More on the subject:
Read all latest stories

Related articles

Photo

Multiple tumor tissue biomarkers

MOSAICA: next-generation biopsy technology

A new biopsy tool will enable scientists and clinicians to simultaneously profile many biomarkers in cells and tissues.

Photo

Potential game-changer

Telling COVID-19 apart from influenza

Researchers have developed a diagnostic for SARS-CoV-2 that is capable of differentiating between COVID-19 and the garden-variety bug with fast turnaround.

Photo

Mini-microscopes

Are disposable robots conquering the labs of the future?

The team at the Institute of Medical Device Technology at the University of Stuttgart, Germany, is developing methods to produce top-quality medical devices at affordable prices. Professor Dr Peter…

Related products

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
ASP Lab Automation – Bench-top Decapper DeCap Pro

Sample Processing

ASP Lab Automation – Bench-top Decapper DeCap Pro

ASP Lab Automation AG
ASP Lab Automation – Recapper KapSafe

Sample Processing

ASP Lab Automation – Recapper KapSafe

ASP Lab Automation AG
ASP Lab Automation – Tube Sorter SortPro

Sample Processing

ASP Lab Automation – Tube Sorter SortPro

ASP Lab Automation AG
Subscribe to Newsletter